CONCERNED ABOUT
YOUR PRIVACY?
OBR takes your privacy
seriously. Please read the
following to learn more
about our privacy policy.
ARE
YOU A CATALYST?
We at OBR believe you are. That's why we are dedicated to providing you with instantaneous oncology news, provocative journalism, topical discussion, and a place to track performance of oncology products, markets, companies, and people.
BECOME A CATALYST.
SUBSCRIBE TO
ONCOLOGY BUSINESS REVIEW
TODAY.
Oncology Business Review is the first and only journal of its kind that utilizes in-depth interviews, news coverage, various data sources, and insightful commentary to provide provocative discussion for people who work in and honestly care about the commercial oncology industry. We, here at Oncology Business Review, define commercial oncology as the medical affairs, finance, marketing, legal, regulatory, sales force, reimbursement, and all other departments that make a company developing or marketing oncology products tick.
At Oncology Business Review we try and incorporate the perspectives of all the oncology stakeholders (i.e. the oncologist, nurse, practice manager, government, and industry) as we investigate and report on the latest news in the industry of oncology. When you read an issue of Oncology Business Review you’ll see original journalism on insightful topics and sometimes you’ll see information reporting on and tracking our industry’s trends. In some cases you’ll see information available elsewhere but repackaged to give you one resource for all your oncology industry information.
Our goal is to provide at least 5 feature articles each issue and 10 issues per year. These feature articles will tackle hot topics and trends in the industry each issue. In addition to the feature articles, there will be recurring sections such as ODAC Scheduler, Legal & Regulatory News, On-College (an oncology learning space), Pipeline Perspectives, Onconomy, Market Research Matters, and the Tumor Ticker and OBR Index. All these sections are designed to keep you up-to-date on trends and highlights occurring in the oncology industry.